Painreform Ltd (PRFX)

$1.42 +0.02 (1.07%)
Market Cap 2.82M
Revenue (ttm) 0.00
Net Income (ttm) -14.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 35,148
Avg Vol 224,918
Day's Range N/A - N/A
Shares Out 2.01M
Stochastic %K 45%
Beta 0.56
Analysts Strong Buy
Price Target $47.99

Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operatio...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 7177050
Address:
65 Yigal Alon St., Tel Aviv, Israel
Weimanator
Weimanator Jul. 2 at 6:11 PM
$PRFX getting some slaps
0 · Reply
Weimanator
Weimanator Jun. 30 at 3:46 AM
$PRFX get ready for some excitement this week!
0 · Reply
Weimanator
Weimanator Jun. 27 at 6:31 PM
$PRFX no its dumping!!! Everyone sell their shares to me!!!
0 · Reply
max315
max315 Jun. 27 at 1:28 PM
$PRFX still holding 1.28s. They'll find it.
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:13 PM
$PRFX 1.80 ask goes then this is going above 2
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:11 PM
$PRFX today this touched 52 week low 1.25 But in premarket it toyched 1.21 I am seeing this will go above 2 soon and Swing trade
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:06 PM
$PRFX Israel based Lots of pharma companies I noticed $PYPD
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:04 PM
$PRFX I entered in premarket and after market and bought my average is 50k is 1.34 I am seeing this above $2 soon and more
1 · Reply
max315
max315 Jun. 26 at 4:13 PM
$PRFX finally starting to creep up
0 · Reply
StockFlips
StockFlips Jun. 26 at 3:57 PM
$PRFX looks interesting 🤔
0 · Reply
Latest News on PRFX
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 27, 2025, 12:12 PM EDT - 5 weeks ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

May 7, 2025, 4:30 PM EDT - 2 months ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

Apr 10, 2025, 8:30 AM EDT - 3 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

PainReform Provides Year-End Business Update

Apr 7, 2025, 5:00 PM EDT - 3 months ago

PainReform Provides Year-End Business Update

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Mar 5, 2025, 11:00 AM EST - 4 months ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Feb 18, 2025, 8:30 AM EST - 4 months ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Dec 27, 2024, 8:30 AM EST - 6 months ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 20, 2024, 8:30 AM EST - 8 months ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Nov 7, 2024, 5:00 PM EST - 8 months ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 11, 2024, 8:30 AM EDT - 10 months ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Sep 10, 2024, 9:46 AM EDT - 10 months ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 20, 2024, 8:30 AM EDT - 11 months ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 7, 2024, 10:00 AM EDT - 11 months ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 31, 2024, 4:15 PM EDT - 1 year ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Provides Business Update for the First Quarter of 2024

May 15, 2024, 4:05 PM EDT - 1 year ago

PainReform Provides Business Update for the First Quarter of 2024

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

May 8, 2024, 8:30 AM EDT - 1 year ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

PainReform Announces Closing of $4 Million Public Offering

Apr 18, 2024, 2:19 PM EDT - 1 year ago

PainReform Announces Closing of $4 Million Public Offering

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 9, 2024, 9:00 AM EDT - 1 year ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Apr 2, 2024, 8:30 AM EDT - 1 year ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform to Present at the Microcap Conference in Atlantic City

Jan 22, 2024, 8:30 AM EST - 1 year ago

PainReform to Present at the Microcap Conference in Atlantic City

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Jan 3, 2024, 8:30 AM EST - 1 year ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Dec 26, 2023, 6:00 PM EST - 1 year ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

PainReform Provides Business Update for the Third Quarter of 2023

Nov 15, 2023, 4:05 PM EST - 1 year ago

PainReform Provides Business Update for the Third Quarter of 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 11, 2023, 8:30 AM EDT - 1 year ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 7, 2023, 10:00 AM EDT - 1 year ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Sep 5, 2023, 8:30 AM EDT - 1 year ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

PainReform Provides Business Update for the Second Quarter of 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 19, 2023, 9:00 AM EDT - 2 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 14, 2023, 2:35 PM EDT - 2 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 2 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 15, 2023, 8:30 AM EDT - 2 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Jun 7, 2023, 4:30 PM EDT - 2 years ago

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Provides Business Update for the First Quarter of 2023

May 15, 2023, 4:45 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2023

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 1, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

Mar 28, 2023, 9:10 AM EDT - 2 years ago

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Mar 16, 2023, 8:00 AM EDT - 2 years ago

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Feb 7, 2023, 4:05 PM EST - 2 years ago

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

PainReform Provides Business Update for the Third Quarter of 2022

Nov 15, 2022, 8:30 AM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2022

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 1, 2022, 8:00 AM EDT - 3 years ago

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PainReform Provides Business Update for the Second Quarter of 2022

Aug 16, 2022, 8:05 AM EDT - 3 years ago

PainReform Provides Business Update for the Second Quarter of 2022

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

Apr 12, 2022, 9:00 AM EDT - 3 years ago

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

Mar 21, 2022, 9:25 AM EDT - 3 years ago

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

Mar 17, 2022, 8:00 AM EDT - 3 years ago

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

Dec 14, 2021, 8:30 AM EST - 3 years ago

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

PainReform Provides Business Update for the Third Quarter of 2021

Nov 16, 2021, 8:00 AM EST - 3 years ago

PainReform Provides Business Update for the Third Quarter of 2021

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

Oct 14, 2021, 8:30 AM EDT - 4 years ago

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

PainReform Provides Business Update for the Second Quarter of 2021

Aug 16, 2021, 8:00 AM EDT - 4 years ago

PainReform Provides Business Update for the Second Quarter of 2021

PainReform Provides Business Update for the First Quarter of 2021

May 13, 2021, 8:15 AM EDT - 4 years ago

PainReform Provides Business Update for the First Quarter of 2021

PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

Mar 18, 2021, 9:15 AM EDT - 4 years ago

PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

Weimanator
Weimanator Jul. 2 at 6:11 PM
$PRFX getting some slaps
0 · Reply
Weimanator
Weimanator Jun. 30 at 3:46 AM
$PRFX get ready for some excitement this week!
0 · Reply
Weimanator
Weimanator Jun. 27 at 6:31 PM
$PRFX no its dumping!!! Everyone sell their shares to me!!!
0 · Reply
max315
max315 Jun. 27 at 1:28 PM
$PRFX still holding 1.28s. They'll find it.
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:13 PM
$PRFX 1.80 ask goes then this is going above 2
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:11 PM
$PRFX today this touched 52 week low 1.25 But in premarket it toyched 1.21 I am seeing this will go above 2 soon and Swing trade
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:06 PM
$PRFX Israel based Lots of pharma companies I noticed $PYPD
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 7:04 PM
$PRFX I entered in premarket and after market and bought my average is 50k is 1.34 I am seeing this above $2 soon and more
1 · Reply
max315
max315 Jun. 26 at 4:13 PM
$PRFX finally starting to creep up
0 · Reply
StockFlips
StockFlips Jun. 26 at 3:57 PM
$PRFX looks interesting 🤔
0 · Reply
Weimanator
Weimanator Jun. 26 at 1:25 PM
$PRFX crazy to me how people aren’t seeing what’s happening here. This is the most action outside of pump and dumps this stock has seen for the last year easy. I’m ready for a show!
0 · Reply
AlihsaN78
AlihsaN78 Jun. 26 at 9:17 AM
$PRFX Something coming but we dont know in which direction because this oversold is anormal...when the price will be bottom , it will boom... This is Israel company.
0 · Reply
nevoG
nevoG Jun. 26 at 8:28 AM
$PRFX selling is hard…
0 · Reply
max315
max315 Jun. 25 at 8:35 PM
$PRFX over 2 and she skips to 3. But happy with my entry today. Hope I'm not looking away when it runs lol
1 · Reply
AlihsaN78
AlihsaN78 Jun. 25 at 8:27 PM
$PRFX this stock is a joke...i will delete from my watchlist..idiot
1 · Reply
max315
max315 Jun. 25 at 7:24 PM
$PRFX full size at 1.17 if we get there, and stop under 1.10 (obviously). Patient swing from here.
1 · Reply
max315
max315 Jun. 25 at 7:05 PM
$PRFX starter 1.28.
0 · Reply
AlihsaN78
AlihsaN78 Jun. 25 at 5:30 PM
$PRFX totally diffetent from pre market..move baby
2 · Reply
buywhenhurt
buywhenhurt Jun. 25 at 2:59 PM
$PRFX drifting down on low Volume, can bounce back easily with a little buying volume
1 · Reply
AlihsaN78
AlihsaN78 Jun. 25 at 2:38 PM
$PRFX wtf is going on...ahahahaah..idiot stock
1 · Reply
Weimanator
Weimanator Jun. 25 at 1:54 PM
$PRFX if any of you have seen this baby move you know something big is about to happen! Let’s goooo!!!
0 · Reply
Weimanator
Weimanator Jun. 25 at 1:37 PM
$PRFX got to love it! Time is money!
0 · Reply